MDL 73005EF hydrochloride

Pricing Availability   Qty
Cat.No. 0411 - MDL 73005EF hydrochloride | C20H26N2O4.HCl | CAS No. 102908-60-1
Description: Potent and selective 5-HT1A partial agonist
Chemical Name: 8-[2-(1,4-Benzodioxan-2-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride
Purity: ≥98% (HPLC)
Literature (5)

Biological Activity

Potent and selective 5-HT1A receptor antagonist. Has partial agonist properties.

Technical Data

M. Wt 394.9
Formula C20H26N2O4.HCl
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 102908-60-1
PubChem ID 56972149

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solubility Soluble to 25 mM in water

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:


References are publications that support the biological activity of the product.

Buisson Defferier and Van den Buuse (1992) Cardiovascular effects of the 5-HT1A receptor ligand, MDL 73005EF, in conscious hypertensive rats. Eur.J.Pharmacol. 223 133 PMID: 1362161

Gartside et al (1990) Effects of MDL 73005EF on central pre-and-postsynaptic 5HT1A receptor function in the rat in vivo. Eur.J.Pharmacol. 191 391 PMID: 1964908

Van der Hooff and Galvan (1991) Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal slice. Eur.J.Pharmacol. 196 291 PMID: 1893914

If you know of a relevant reference for MDL 73005EF hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all 5-HT1A Receptor Agonists

Keywords: MDL 73005EF hydrochloride, MDL 73005EF hydrochloride supplier, Potent, selective, 5-HT1A, partial, agonists, Serotonin, Receptors, 5-HT1, MDL73005EF, hydrochloride, 0411, Tocris Bioscience

Citations for MDL 73005EF hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for MDL 73005EF hydrochloride. Do you know of a great paper that uses MDL 73005EF hydrochloride from Tocris? Please let us know.

Reviews for MDL 73005EF hydrochloride

There are currently no reviews for this product. Be the first to review MDL 73005EF hydrochloride and earn rewards!

Have you used MDL 73005EF hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.